Bionomics is a biopharmaceutical company dedicated to making better treatments for central nervous system disorders such as anxiety, depression and Alzheimer's disease. Bionomics is in a strong growth phase with its world-class portfolio of promising drug candidates from early to advanced stages of clinical development. This portfolio is underpinned by drug discovery platforms that include MultiCore®, its proprietary chemistry capability. In terms of strategy, Bionomics partners with large pharmaceutical companies to progress drugs through the later stages of development and market launch. This means it can focus its strengths on innovative drug discovery, with particular emphasis on drugs for ion channel targets.